These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 30987257)

  • 1. Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?
    von der Grün J; Rödel F; Brandts C; Fokas E; Guckenberger M; Rödel C; Balermpas P
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30987257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Patel B; Saba NF
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
    Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
    Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The Immune Checkpoints Inhibitors for Head and Neck Cancer].
    Yokota T
    Gan To Kagaku Ryoho; 2019 Jan; 46(1):21-27. PubMed ID: 30765636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
    Bhatia A; Burtness B
    Drugs; 2023 Feb; 83(3):217-248. PubMed ID: 36645621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Agulnik M
    Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.
    Ng K; Metcalf R; Sacco J; Kong A; Wheeler G; Forsyth S; Bhat R; Ward J; Ensell L; Lowe H; Spanswick V; Hartley J; White L; Lloyd-Dehler E; Forster M
    BMJ Open; 2023 Nov; 13(11):e070391. PubMed ID: 38011968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Argiris A; Harrington KJ; Tahara M; Schulten J; Chomette P; Ferreira Castro A; Licitra L
    Front Oncol; 2017; 7():72. PubMed ID: 28536670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
    Goss GD; Spaans JN
    Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
    Kok VC
    Front Oncol; 2020; 10():268. PubMed ID: 32185135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Taberna M; Oliva M; Mesía R
    Front Oncol; 2019; 9():383. PubMed ID: 31165040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
    Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for squamous cell carcinoma of the head and neck.
    Yokota T; Homma A; Kiyota N; Tahara M; Hanai N; Asakage T; Matsuura K; Ogawa T; Saito Y; Sano D; Kodaira T; Motegi A; Yasuda K; Takahashi S; Tanaka K; Onoe T; Okano S; Imamura Y; Ariizumi Y; Hayashi R;
    Jpn J Clin Oncol; 2020 Sep; 50(10):1089-1096. PubMed ID: 32776100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.